Summit Therapeutics Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; unaudited consolidated results. Dollar figures below are in millions unless noted. Summit is a development-stage biopharmaceutical company with no approved or marketed drugs.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | $0.250 | $0.192 |
| Research and development expense | $20.556 | $18.379 |
| General and administrative expense | $6.659 | $4.185 |
| Other operating income | $4.807 | $5.449 |
| Operating loss | $(22.158) | $(16.923) |
| Net loss | $(21.397) | $(17.488) |
| Net loss per share, basic and diluted | $(0.22) | $(0.21) |
| Operating cash used | $(19.001) | $(20.669) |
Revenue was primarily license-related income recognized over time under the Eurofarma agreement, not product sales. No profit or positive operating margin was reported; margins are not meaningful given the small revenue base and operating losses.
Cash was $77.450 at March 31, 2022, compared with $71.791 at year-end 2021. Current assets were $99.435 and current liabilities $22.724. Research and development tax-credit receivables totaled $16.945, including $15.290 current and $1.655 non-current. Total liabilities were $52.065, including a $25.055 related-party promissory note payable to CEO and Executive Chairman Robert W. Duggan; the note is unsecured, bears interest at prime, and is due on a qualifying public offering or 18 months after issuance. Financing cash flow included $25.000 from that note. Ending cash was $77.450.
Changes and management commentary
- Net loss increased by about $3.9 million year over year. R&D expense rose $2.2 million and G&A rose $2.5 million, partly offset by lower other operating income. Higher stock-based compensation and headcount contributed to expense growth.
- CDI program spending fell $1.4 million as the pivotal ridinilazole trials were no longer actively enrolling; antibiotic pipeline spending increased, including preclinical work on SMT-738.
- Operating cash use was lower than in Q1 2021, but financing proceeds were also lower. Cash increased by $5.659 million during the quarter.
- Management expects continuing operating losses and stated available resources were expected to fund operating costs and working capital into the third quarter of 2023. This estimate assumes no additional grant or clinical-trial-support funding and may prove incorrect; management expects to need additional capital thereafter.
Pipeline, outlook, and risks
- The December 2021 Phase III Ri-CoDIFy study of ridinilazole for C. difficile infection showed a numerically higher sustained clinical response than vancomycin but did not meet its primary superiority endpoint. Management was evaluating next steps, further analyses, and possible partnership opportunities; no specific development plan or financial guidance was provided in this filing.
- The FDA had previously disagreed with the company’s proposed change to the primary endpoint when combining two Phase III trials. The filing describes continued evaluation of the study data, including analyses for potential submission to the FDA.
- BARDA had not exercised its final independent option for additional ridinilazole funding. Its contract was extended through December 2022 at no cost to close out activities. CARB-X funding supports SMT-738; the filing describes potential additional funding subject to milestones.
- Funding needs, the ability to raise capital on acceptable terms, future ridinilazole decisions, and reduced U.K. R&D tax-credit eligibility as clinical spending declines are key uncertainties. Equity financing could dilute shareholders; debt or partnering could impose restrictions or require surrendering rights.
- The company cited potentially adverse effects from COVID-19 and changing U.S. and U.K. tax rules. It reported no material legal proceedings and no material changes to previously disclosed risk factors other than the added tax-law risk. Management assessed disclosure controls as effective at a reasonable level of assurance.
Important facts for investors to verify
- Whether management’s cash-runway estimate into Q3 2023 remains supportable and what financing or partnership plans are being pursued.
- Updates on ridinilazole’s post-Phase III path, additional analyses, regulatory discussions, and any partnership arrangement.
- The terms, interest accrual, and repayment trigger for the $25 million related-party note, including the potential conflict associated with the lender being the CEO and controlling shareholder.
- Expected BARDA close-out funding, CARB-X milestone eligibility, and the timing and collectability of U.K. R&D tax credits.
- Future spending and development milestones for SMT-738 and other pipeline programs, as well as dilution from outstanding options and warrants.